Distribution of carbapenem resistant Acinetobacter Baumannii and Pseudomonas aeruginosa and ESBL-producing organisms colonization among intensive care patients
- 3k Downloads
KeywordsImipenem Meropenem Colistin Carbapenems Tigecycline
Introduction / objectives
Infection with carbapenem resistant A. baumannii (CR-AB)and P. aeruginosa (CR-PS) as well as ESBL-producing organisms have caused high rate of mortality. This project was aimed to survey the prevalence of drug resistant organisms colonization in critical care patients as a part of infection control program.
Perianal swab, urine (from Foley’s catheter) and endotracheal catheter (ET) were collected from patients who were admitted to intensive care units of a 1000-bed hospital. Isolation of CR-AB and CR-PS was using EMB agar containing 12 ug/ml of either imipenem or meropenem. The MacConkey agar containing 1 ug/ml of cefotaxime was used for screening of ESBL-producing organisms. The MIC of these organisms was performed using THANF customised panel (Sensititre, UK).
A total of 81 isolates was detected from 39 patients. There were 53, 22 and 6 isolates of ESBL-producing organisms, CR-AB and CR-PS, respectively. Perianal was found to be the most common site for colonisation with ESBL-producing organisms (45/60 isolates) while 8 of 14 isolates from ET were CR-AB. All CR-AB isolates resisted to nearly all tested antibiotics. However, all isolates were susceptible to colistin and tigecycline with the MIC90 at ≤1 and 1 ug/ml, respectively. In contrast, the ESBL-producing organisms remained susceptible to all tested carbapenems. Nevertheless, 68% of these isolates resisted to fluoroquinolones.
This project is a part of implementation of hospital-acquired infection control policy. The data demonstrated the existing of various multiple-drugs resistant organisms in critical care patients which would be a challenging task for infectious control.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.